DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA

Core Viewpoint - DiaMedica Therapeutics Inc. has successfully completed a pre-IND meeting with the FDA regarding the evaluation of DM199 for preeclampsia treatment [1] Group 1: Company Developments - The company is focused on developing novel treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke [1] - The FDA meeting confirmed the agency's request for one additional non-clinical study before proceeding [1]